Peptides · Therapeutic Peptides
Main Therapeutic Peptides
39 Main Therapeutic Peptides products available from Unibest, part of our therapeutic peptides portfolio.
Available products
39 products currently listed. Request specifications, analytical data or a quotation for any item below.
| Product Name | CAS No. | Comments |
|---|---|---|
| Semaglutide | 910463-68-2 | Originator：Novo Nordisk Approver indications：Obesity,Overweight,Type II diabetes Target：GLP1R |
| Tirzepatide | 2023788-19-2 | Originator：ELI LILLY AND CO Approver indications：Type II diabetes Target：GLP-1R/GIPR |
| Linaclotide | 851199-59-2 | Originator：ABBVIE INC Approver indications：IBS-C/CIC/ FC Target：GC-C |
| Desmopressin acetate | 16789-98-3 | Originator：Ferring Pharmaceuticals Approver indications：Central/nephrogenic diabetes insipidus/ nocturnal enuresis Target：V2 receptor |
| Plecanatide | 467426-54-6 | Originator：SALIX PHARMACEUTICALS INC Approver indications：IBS-C/CIC Target：GC‑C |
| Oxytocin | 50-56-6 | Originator：SANDOZ INC Approver indications：Labor induction & augmentation/Postpartum hemorrhage/Incomplete abortion Target：OXTR |
| Abaloparatide | 247062-33-5 | Originator：RADIUS HEALTH INC Approver indications：Postmenopausal women with osteoporosis at high risk for fracture Target：PTH1R |
| Eptifibatide | 188627-80-7 | Originator：MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC Approver indications：ACS/PCI Target：GP IIb/IIIa |
| Lanreotide | 108736-35-2 | Originator：IPSEN PHARMA BIOTECH SAS Approver indications：Acromegaly Target：SSTR2、SSTR5 |
| Liraglutide | 204656-20-2 | Originator：NOVO NORDISK INC Approver indications：Type II diabetes mellitus Target：GLP-1R |
| Octreotide acetate | 83150-76-9 | Originator：NOVARTIS Approver indications：Acromegaly Target：SSTR2、SSTR5 |
| Icatibant | 30308-48-4 | Originator：TAKEDA PHARMACEUTICALS USA INC Approver indications：HAE Target：Bradykinin B2 receptor |
| Enfuvirtide | 15919-65-0 | Originator：HOFFMANN LA ROCHE INC Approver indications：Treatment-experienced patients with HIV-1 infection Target：HIV‑1 gp41 |
| Teduglutide | 197922-42-2 | Originator：TAKEDA PHARMACEUTICALS USA INC Approver indications：Short Bowel Syndrome Target：GLP-2R |
| Teriparatide | 12583-68-5 | Originator：ELI LILLY AND CO Approver indications：Osteoporosis in patients at high risk of fractures Target：PTH1 receptor |
| Cetrorelix acetate | 120287-85-6/130143-01-0 | Originator：EMD SERONO INC Approver indications：Inhibition of premature LH surges Target：GnRH-R |
| Ziconotide acetate | 107452-89-1 | Originator：TERSERA THERAPEUTICS LLC Approver indications：The management of severe chronic pain Target：CaV2.2 |
| Sincalide | 25126-32-3 | Originator：BRACCO DIAGNOSTICS INC Approver indications：Stimulate gallbladder contraction/Stimulate pancreatic secretion/Accelerate the transit of a barium meal through the small bowel Target：CCK1R |
| Vasopressin | 11000-17-2 | Originator：ENDO OPERATIONS LTD Approver indications：Increase blood pressure Target：vascular V1 receptors |
| Pramlintide acetate | 196078-30-5 | Originator：ASTRAZENECA AB Approver indications：For use in combination with insulin in patients with type 1 and type 2 diabetes to improve postprandial glycemic control. Target：AMY receptor |
| Degarelix acetate | 214766-78-6 | Originator：FERRING PHARMACEUTICALS INC Approver indications：Advanced prostate cancer Target：GnRH receptor |
| Lypressin | 50-57-7 | Originator：NOVARTIS PHARMACEUTICALS CORP Approver indications：Central Diabetes Insipidus Target：AVPR2 |
| Bivalirudin | 128270-60-0 | Originator：SANDOZ INC Approver indications：Thrombin inhibitor Target：Thrombin, F2 |
| Protirelin | 24305-27-9 | Originator：ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV Approver indications：Diagnostic Test Target：TRH-R |
| Terlipressin acetate | 14636-12-5 | Originator：MALLINCKRODT PHARMACEUTICALS IRELAND LTD Approver indications：HRS-1 Target：V1 Receptor |
| Ganirelix acetate | 123246-29-7 | Originator：ORGANON USA LLC A SUB OF ORGANON AND CO Approver indications：Preventing an early LH surge during ovarian stimulation cycles (COH) Target：GnRH receptor |
| Teriparatide acetate | 52232-67-4 | Originator：SANOFI AVENTIS US LLC Approver indications：/ Target：/ |
| Glucagon HCL | 11140-85-5 | Originator：ELI LILLY AND CO Approver indications：Severe hypoglycemia Target：Glucagon receptor |
| Vosoritide | 1480724-61-5 | Originator：BIOMARIN PHARMACEUTICAL INC Approver indications：Achondroplasia Target：NPR‑B |
| Octreotide Acetate | 79517-01-4 | Originator：NOVARTIS PHARMACEUTICALS CORP Approver indications：Acromegaly/Carcinoid Syndrome/VIPoma Target： SSTR2/SSTR5 |
| Triptorelin Pamoate | 124508-66-3 | Originator：VERITY PHARMACEUTICALS INC Approver indications：Prostate cancer Target：GnRH receptor |
| Goserelin Acetate | 145781-92-6 | Originator：TERSERA THERAPEUTICS LLC Approver indications：Carcinoma of the prostate/Palliative treatment of advanced carcinoma of the prostate / The management of endometriosis/Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding/Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women Target：GnRH receptor |
| Degarelix | 214766-78-6 | Originator：FERRING PHARMACEUTICALS INC Approver indications：Advanced Hormone-dependent Prostate Cancer。 Target：GnRH receptor |
| Carbetocin | 37025-55-1 | Originator：Ferring Pharmaceuticals Approver indications：Postpartum hemorrhage Target：Oxytocin receptor |
| Nesiritide | 124584-08-3 | Originator：SCIOS LLC Approver indications：Treatment of acutely decompensated chronic congestive heart failure with dyspnea at rest Target：NPR‑A |
| Glatiramer Acetate | 147245-92-9 | Originator：TEVA PHARMACEUTICALS USA Approver indications：Relapsing forms of multiple sclerosis (MS) Target：Th2 type T cells/Phagocytes-mixed T cells |
| Glucagon | 16941-32-5 | Originator：ELI LILLY AND CO Approver indications：Severe hypoglycemia Target：GCGR |
| Abarelix | 183552-38-7 | Originator：SPECIALITY EUROPEAN PHARMA LTD Approver indications：Advanced prostate cancer Target：GnRH |
| Etelcalcetide | 1262780-97-1 | Originator：KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC Approver indications：Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis Target：CaSR |
Related Therapeutic Peptides subcategories
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →